R
REGENXBIO Inc. (RGNX)
NMS – Real Time Price. Currency in USD
10.48
+0.24 (2.34%)
At close: Jun 26, 2026, 4:00 PM EDT
10.34
-0.14 (-1.34%)
After-hours: Jun 26, 2026, 7:52 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
10.48
+0.24 (2.34%)
At close: Jun 26, 2026, 4:00 PM EDT
10.34
-0.14 (-1.34%)
After-hours: Jun 26, 2026, 7:52 PM EDT
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
| Name | Position |
|---|---|
| Dr. Jahannaz Dastgir D.O. | Clinical Development Lead |
| Dr. Olivier Danos Ph.D. | Executive VP & Chief Scientific Officer |
| Dr. Ram Palanki Pharm.D. | Executive VP & Chief Commercial Officer |
| Dr. Stephen Pakola M.D. | Executive VP & Chief Medical Officer |
| Mr. Craig Malzahn | Executive VP of Product Development & CTO |
| Mr. Curran M. Simpson M.S. | President, CEO & Director |
| Mr. Mitchell Chan M.B.A. | Executive VP & CFO |
| Mr. Patrick J. Christmas II, J.D. | Executive VP & Chief Strategy and Legal Officer |
| Ms. Nina Hunter | SVP of Global Regulatory Strategy and Quality |
| Ms. Shiva G. Fritsch | Chief Communications & People Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-03 | SC TO-I | rgnx-20260603.htm |
| 2026-06-03 | 8-K | rgnx-20260529.htm |
| 2026-05-14 | 8-K | rgnx-20260514.htm |
| 2026-05-14 | 10-Q | rgnx-20260331.htm |
| 2026-04-14 | DEF 14A | rgnx-20260414.htm |
| 2026-04-14 | ARS | rgnx-ars-2025.pdf |
| 2026-04-03 | PRE 14A | rgnx-20260403.htm |
| 2026-03-20 | 8-K | rgnx-20260318.htm |
| 2026-03-05 | 8-K | rgnx-20260305.htm |
| 2026-03-05 | 10-K | rgnx-20251231.htm |